New symmetrical quinazoline derivatives selectively induce apoptosis in human cancer cells

Area of Science:

• Medicinal Chemistry
• Cancer Biology
• Pharmacology

Background:

• Development of novel anticancer agents is crucial for improved cancer therapy.
• Selective induction of apoptosis in cancer cells is a key therapeutic strategy.
• Quinazoline derivatives have shown potential as anticancer agents.

Purpose of the Study:

• To discover novel symmetrical quinazoline derivatives with selective anticancer activity.
• To evaluate the in vitro cytotoxic effects and proapoptotic mechanisms of these compounds.
• To identify lead compounds for further investigation as anticancer drugs.

Main Methods:

• In vitro screening of quinazoline derivatives against human breast, colon, and bladder cancer cell lines.
• Determination of IC(50) values for cytotoxic compounds.
• Assays for caspase-3 activation, chromatin degradation, and apoptosis.
• Evaluation of compound selectivity using non-tumoral human cell lines.
• Detailed mechanistic studies of the lead compound, JRF12 (2,4-dibenzylaminoquinazoline), including cell cycle analysis and gene expression profiling (oligonucleotide microarrays, Q-RT-PCR).

Main Results:

• Several quinazoline derivatives exhibited cytotoxic effects against cancer cell lines.
• JRF12 (2,4-dibenzylaminoquinazoline) demonstrated significant anticancer activity and selectivity.
• JRF12 induced caspase-3 activation and nuclear chromatin degradation, indicating apoptosis.
• Cell cycle analysis revealed a decrease in G(1) phase and an increase in G(2) phase cells prior to cell death.
• Gene expression analysis showed minimal changes, suggesting a transcription-independent mechanism.

Conclusions:

• 2,4-dibenzylaminoquinazoline (JRF12) is a promising anticancer drug candidate.
• JRF12 exhibits cytostatic and apoptotic effects, primarily through a transcription-independent pathway.
• The compound's selectivity for cancer cells warrants further investigation for therapeutic development.